Interactions between wild-type and mutant Ras genes in lung and skin carcinogenesis

Oncogene

Volumn 32, Issue 34, 2013, Pages 4028-4033

  To, M D ^a,b   Rosario, R D ^b   Westcott, P M K ^b,c   Banta, K L ^b   Balmain, A ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Hras; Kras; Lung carcinogenesis; Nras; Ras; Skin carcinogenesis

Indexed keywords

CARCINOGEN; RAS PROTEIN;

ALLELE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEVELOPMENT; GENE DELETION; GENE INTERACTION; LUNG CARCINOGENESIS; MOUSE; NEOPLASM; NONHUMAN; ONCOGENE H RAS; ONCOGENE RAS; PAPILLOMA; PRIORITY JOURNAL; PROTEIN FAMILY; PROTO ONCOGENE; SKIN CARCINOGENESIS; SKIN PAPILLOMA; SQUAMOUS CELL CARCINOMA; TUMOR INVASION; TUMOR VOLUME; WILD TYPE;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; EPISTASIS, GENETIC; FEMALE; GENES, RAS; LUNG; LUNG NEOPLASMS; MALE; MICE; MICE, KNOCKOUT; MODELS, GENETIC; MUTATION; RAS PROTEINS; SKIN; SKIN NEOPLASMS; URETHANE;

MUS;

EID: 84883186892     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.404     Document Type: Article

References (29)

1. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682-4689.
2. Balmain A, Pragnell IB. Mouse skin carcinomas induced in vivo by chemical carcinogens have a transforming Harvey-ras oncogene. Nature 1983; 303: 72-74.
3. You M, Candrian U, Maronpot RR, Stoner GD, Anderson MW. Activation of the Ki-ras protooncogene in spontaneously occurring and chemically induced lung tumors of the strain A mouse. Proc Natl Acad Sci USA 1989; 86: 3070-3074.
4. To MD, Wong CE, Karnezis AN, Del Rosario R, Di Lauro R, Balmain A. Kras regulatory elements and exon 4A determine mutation specificity in lung cancer. Nat Genet 2008; 40: 1240-1244.
5. Manenti G, Trincucci G, Pettinicchio A, Amendola E, Scarfo M, Dragani TA. Cis-acting genomic elements of the Pas1 locus control Kras mutability in lung tumors. Oncogene 2008; 27: 5753-5758.
6. Bremner R, Balmain A. Genetic changes in skin tumor progression: correlation between presence of a mutant ras gene and loss of heterozygosity on mouse chromosome 7. Cell 1990; 61: 407-417.
7. Buchmann A, Ruggeri B, Klein-Szanto AJ, Balmain A. Progression of squamous carcinoma cells to spindle carcinomas of mouse skin is associated with an imbalance of H-ras alleles on chromosome 7. Cancer Res 1991; 51: 4097-4101.
8. Modrek B, Ge L, Pandita A, Lin E, Mohan S, Yue P et al. Oncogenic activating mutations are associated with local copy gain. Mol Cancer Res 2009; 7: 1244-1252.
9. Sweet-Cordero A, Tseng GC, You H, Douglass M, Huey B, Albertson D et al. Comparison of gene expression and DNA copy number changes in a murine model of lung cancer. Genes Chromosomes Cancer 2006; 45: 338-348.
10. To MD, Quigley DA, Mao JH, Del Rosario R, Hsu J, Hodgson G et al. Progressive genomic instability in the FVB/Kras(LA2) mouse model of lung cancer. Mol Cancer Res 2011; 9: 1339-1345.
11. Zhang Z, Wang Y, Vikis HG, Johnson L, Liu G, Li J et al. Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat Genet 2001; 29: 25-33.
12. To MD, Perez-Losada J, Mao JH, Hsu J, Jacks T, Balmain A. A functional switch from lung cancer resistance to susceptibility at the Pas1 locus in Kras2LA2 mice. Nat Genet 2006; 38: 926-930.
13. Diaz R, Lue J, Mathews J, Yoon A, Ahn D, Garcia-Espana A et al. Inhibition of Ras oncogenic activity by Ras protooncogenes. Int J Cancer 2005; 113: 241-248.
14. Johnson L, Greenbaum D, Cichowski K, Mercer K, Murphy E, Schmitt E et al. K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes Dev 1997; 11: 2468-2481.
15. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 2001; 15: 3243-3248.
16. Tuveson DA, Shaw AT, Willis NA, Silver DP, Jackson EL, Chang S et al. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 2004; 5: 375-387.
17. Ise K, Nakamura K, Nakao K, Shimizu S, Harada H, Ichise T et al. Targeted deletion of the H-ras gene decreases tumor formation in mouse skin carcinogenesis. Oncogene 2000; 19: 2951-2956.
18. Nagase H, Bryson S, Cordell H, Kemp CJ, Fee F, Balmain A. Distinct genetic loci control development of benign and malignant skin tumours in mice. Nat Genet 1995; 10: 424-429.
19. Hager JH, Hodgson JG, Fridlyand J, Hariono S, Gray JW, Hanahan D. Oncogene expression and genetic background influence the frequency of DNA copy number abnormalities in mouse pancreatic islet cell carcinomas. Cancer Res 2004; 64: 2406-2410.
20. Dworkin AM, Ridd K, Bautista D, Allain DC, Iwenofu OH, Roy R et al. Germline variation controls the architecture of somatic alterations in tumors. PLoS Genet 2010; 6: e1001136.
21. Hennings H, Glick AB, Lowry DT, Krsmanovic LS, Sly LM, Yuspa SH. FVB/N mice: an inbred strain sensitive to the chemical induction of squamous cell carcinomas in the skin. Carcinogenesis 1993; 14: 2353-2358.
22. Perez-Losada J, Balmain A. Stem-cell hierarchy in skin cancer. Nat Rev Cancer 2003; 3: 434-443.
23. Cui W, Fowlis DJ, Bryson S, Duffie E, Ireland H, Balmain A et al. TGFbeta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 1996; 86: 531-542.
24. Diaz R, Ahn D, Lopez-Barcons L, Malumbres M, Perez de Castro I, Lue J et al. The N-ras proto-oncogene can suppress the malignant phenotype in the presence or absence of its oncogene. Cancer Res 2002; 62: 4514-4518.
25. Quinlan MP, Settleman J. Explaining the preponderance of Kras mutations in human cancer: an isoform-specific function in stem cell expansion. Cell Cycle 2008; 7: 1332-1335.
26. Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, Tuveson DA et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 2001; 410: 1111-1116.
27. Lee KE, Bar-Sagi D. Oncogenic KRas suppresses inflammation-associated senescence of pancreatic ductal cells. Cancer Cell 2010; 18: 448-458.
28. Mao JH, To MD, Perez-Losada J, Wu D, Del Rosario R, Balmain A. Mutually exclusive mutations of the Pten and ras pathways in skin tumor progression. Genes Dev 2004; 18: 1800-1805.
29. Nagase H, Mao JH, Balmain A. Allele-specific Hras mutations and genetic alterations at tumor susceptibility loci in skin carcinomas from interspecific hybrid mice. Cancer Res 2003; 63: 4849-4853.